FDA removes positive test requirement for two COVID-19 outpatient therapies
The Food and Drug Administration last week removed the requirement for a positive COVID-19 test result to prescribe Paxlovid to certain adult and pediatric patients and Lagevrio to certain adults at risk of progressing to severe COVID-19. The agency continues to recommend that health care providers use direct SARS-CoV-2 viral testing to help diagnose COVID-19, but said it recognizes that providers may in rare instances diagnose COVID-19 in patients with a negative test result but symptoms and a recent known exposure to COVID-19. For more information, see the updated Paxlovid and Lagevrio fact sheets for health care providers.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…